drugset / Trial / NCT04478227
TPO-Mimetic Use in Children for Hematopoietic Failure
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is an open label, prospective Pilot interventional study will investigate the safety and efficacy of Romiplostim, thrombopoietin (TPO) mimetic, in children (ages: 0 to 21 years) with broad scope of bone marrow failure disorders including acquired and inherited conditions as a first line of therapy along with standard of care.
Timeline
- Start
- 2020-08-18
- Primary completion
- 2024-01-18
- Completion
- 2024-01-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Romiplostim | Peptide | 10 ug/kg | — |
| Subject | Romiplostim | Peptide | 20 ug/kg | — |